DarshanTalks Podcast

Send us Fan Mail

In this episode, Edye Edens and Darshan Kulkarni discuss the evolving landscape of IRB oversight in 2024, including the roles of HRPP, AAHRPP, and OHRP, and the need for greater federal agency involvement. They also cover the impact of new guidance, the Trump administration, and the FDA's relationship with IRBs.

We discuss: 

1. The FDA’s Finalized Guidance on Decentralized Clinical Trials (DCTs):
 The recent FDA guidance formalizing decentralized elements in clinical trials raises critical questions for Institutional Review Boards (IRBs). While DCTs have existed for years, the official guidance now provides a framework for utilizing healthcare providers (HCPs), remote modalities, and flexible patient engagement. IRBs must consider:

• Approval Implications: How decentralized elements affect risk-based assessments and informed consent.
• Data Validity: Whether varying patient experiences impact trial control and data integrity.
• Protocol Design: Increased complexities in evaluating sponsor protocols that integrate hybrid or decentralized approaches.

2. Human Research Protection Programs (HRPPs):
 IRBs are components of broader HRPPs, which also encompass research compliance, conflict of interest management, and quality auditing. Accreditation bodies like AAHRPP (gold standard for HRPPs) demand higher standards, which could necessitate additional adjustments to align with FDA guidance.

3. Regulatory Overlap and Harmonization Challenges:
 IRBs must navigate overlapping jurisdiction from the FDA and other entities like the Office for Human Research Protections (OHRP). The lack of harmonized regulations between these agencies creates confusion for researchers and inefficiencies in clinical trial oversight.

4. FDA Audits and Oversight of IRBs:
 While the FDA does not directly regulate IRBs, it audits them and issues warning letters or Form 483 observations. IRBs must remain vigilant about FDA compliance, especially with decentralized elements becoming more common.

5. Decentralization’s Efficiency Debate:
 There is no blanket conclusion about whether decentralized trials increase efficiency or diversity. IRBs must assess the appropriateness of decentralized approaches on a case-by-case basis, particularly for complex studies like oncology trials or early-phase research requiring hospital stays.

6. Calls for Streamlining Oversight:
 There is growing discussion about reducing redundancy across regulatory bodies to enhance efficiency and lower costs for patients. However, skepticism remains about whether eliminating overlap would ensure adequate protection for trial participants.

7. Future Considerations:

• Adaptation: IRBs must adapt to increased DCT submissions while maintaining rigorous risk-based evaluations.
• Consistency: Balancing flexibility in decentralized models with the need for consistent oversight practices.
• Policy Evolution: Ongoing dialogue on whether accrediting bodies like AAHRPP or agencies like OHRP should develop complementary guidance to align with FDA standards.

In 2024, IRBs face a critical moment to address these challenges while ensuring that decentralized innovations do not compromise participant safety or trial integrity.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The polio vaccine, credited with eradicating a crippling disease in the U.S., faces renewed scrutiny after attorney Aaron Siri, linked to Robert F. Kennedy Jr., petitioned the FDA to revoke its approval. Kennedy, nominated as Health and Human Services Secretary, has distanced himself from the "anti-vaccine" label but calls for further vaccine studies. Public health officials, including Senator Mitch McConnell, stress the vaccine’s proven safety and life-saving impact.

While President-elect Trump has suggested openness to revisiting vaccine policies, the FDA operates independently, guided by rigorous scientific evidence. Any changes to the polio vaccine’s status would require substantial justification and political will. Trust in science and regulatory safeguards remains critical during this ongoing debate.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

FDA has changed its mind about off label marketing. Today, we're diving into how drug and device companies can effectively engage with payers and providers, exploring recent updates and guidelines. 

Let’s start with the basics: FDA Regulations and the First Amendment. The FDA’s ability to impose restrictions on speakers and content is limited by the First Amendment, which protects commercial speech. While the FDA can regulate marketing to prevent false or misleading claims, it must balance this with constitutional protections.

Next, we discuss the CFL Guidance—focused on medical device and product communications consistent with FDA-required labeling. This guidance helps evaluate whether communications about approved products align with FDA labeling, including considerations for patient populations, usage directions, and potential harm. Despite its existence for six years, companies still face challenges due to high penalties for non-compliance and a lack of concrete steps for implementation.

We’ll also cover the FDAMA 114 Guidance, which clarifies how manufacturers can share healthcare economic information with payers about both approved and unapproved products. This guidance aims to ensure that communications are truthful, non-misleading, and based on competent and reliable scientific evidence.

Additionally, the PIE Act (Prescription Drug and Medical Device Pre-Approval Information Exchange Act) facilitates communication about investigational drugs, allowing for early planning and budgeting by providing data on clinical trial phases and anticipated approval timelines.

Finally, we’ll touch on the SIUU Guidance, which focuses on communications from firms to healthcare providers about unapproved uses of approved products. This guidance is designed to ensure that such communications are truthful and separate from promotional content, despite the complexities and scrutiny involved.

The key takeaways for medical affairs teams are to develop strategies that ensure compliance with these diverse guidelines, addressing both regulatory and legal aspects of communication. For robust support, contact the Kulkarni Law Firm, where we provide expert guidance to navigate these complex issues and ensure compliance.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Today, we're discussing the FDA's use of artificial intelligence (AI) to transform clinical trials.

AI is emerging as a cornerstone in clinical research, with the FDA recognizing its potential in several key areas. First, predictive modeling allows AI to optimize pharmacokinetic profiles, streamlining dosing regimens and enhancing trial efficiency. Additionally, AI can create counterfactual simulations, enabling researchers to predict outcomes without putting real patients at risk.

AI also improves adherence through tools like smartphone alerts and electronic medication tracking, ensuring participants remain engaged. By automating administrative tasks and optimizing workflows, AI enhances operational efficiency, significantly reducing the time and costs associated with trial management.

Moreover, AI boosts participant recruitment and diversity by improving insight selection and engagement strategies, while AI-driven chatbots provide real-time support, predicting potential dropouts and improving retention. However, it’s essential to implement proper training and safeguards to prevent overreliance on AI tools.

AI further aids in monitoring safety and predicting adverse events by detecting clusters of symptoms, allowing for timely interventions. Additionally, it streamlines the submission process by automating data analysis and report generation, ensuring compliance and speeding up approvals.

The integration of AI into clinical trials promises to make research more efficient, inclusive, and safe. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The rise of biohacking has transitioned from a niche interest to a mainstream trend, particularly in the context of drugs like Ozempic and ketamine. While biohacking aims to enhance human performance and health, it raises significant questions about the risks and benefits, especially concerning telehealth services. Individuals are increasingly seeking prescriptions for medications traditionally used for specific medical conditions, such as diabetes, and utilizing them off-label for weight loss or mental health treatment without appropriate medical oversight.

This trend poses substantial risks, including misuse, adverse effects, and addiction, particularly with controlled substances like ketamine. Physicians face complex challenges as patients pursue these unregulated therapies, often without the necessary in-person examinations mandated in certain states. The lack of thorough patient assessments and informed consent raises concerns about liability, regulatory scrutiny, and potential malpractice claims.

As telehealth becomes more popular, the gap between patient autonomy and the physician's duty to do no harm widens. Physicians must navigate these evolving issues carefully, ensuring adequate oversight and understanding the risks associated with prescribing these powerful medications.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The FDA’s current approach to AI in healthcare highlights significant gaps in regulatory preparedness. Although the FDA has approved thousands of AI-enabled tools, it still lacks the resources, clear guidelines, and enforcement power necessary to address the rapid advancements and risks of AI effectively. The agency has issued frameworks and adopted some risk-based approaches, but these efforts fall short, leaving companies in limbo and patient safety at risk. AI in healthcare demands consistent oversight, yet the FDA’s “wait-and-watch” approach, often leading to delayed action, hinders industry progress and creates uncertainty for innovators. Addressing these issues requires urgent congressional support, funding, and global regulatory collaboration. At the Kulkarni Law Firm, we help guide companies through this complex regulatory landscape to ensure compliance and safety. For more insights, subscribe to our podcast or reach out today.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, guest host Kate Woods and Darshan Kulkarni delve into current healthcare issues, including the unsettling news of the CEO of United Healthcare being shot. They discuss the broader implications of this event, questioning how it reflects the state of the healthcare system and whether CEOs in troubled companies are becoming targets. The conversation shifts to potential solutions for the healthcare crisis, considering options like Medicare for All and the inefficiencies in drug pricing, where American consumers often subsidize global drug costs. The duo also explores innovation in healthcare, such as adaptive clinical trials, and the role of AI in improving quality and efficiency. They touch on the impact of private equity in healthcare, emphasizing that funding can improve care quality and support staff livelihoods. Overall, the discussion centers on fixing a broken system with a focus on practical changes, accountability, and innovation.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Robert F. Kennedy Jr. has announced plans for a presidential mandate to restore federal agencies, including the FDA, to the "gold standard" of scientific review. This bold proposal has significant implications for the life sciences industry, affecting drug advertisers, clinical researchers, and M&A attorneys.

Key Takeaways by Sector

1. For Drug Advertisers
   • Expect stricter scrutiny on advertising claims, requiring robust, data-driven evidence.
   • Collaborations between marketing, regulatory, and legal teams will become critical to avoid severe penalties for non-compliance.
   • Flashy, minimally substantiated claims are likely to face rejection, reshaping advertising strategies.
2. For Clinical Researchers
   • Enhanced focus on data integrity, transparency, and protocol adherence is anticipated.
   • While this could slow down approvals, it will boost study credibility and public trust.
   • Researchers must align closely with sponsors to meet these stringent new expectations.
3. For M&A Attorneys
   • Due diligence processes will become more complex, requiring careful navigation of stricter regulatory demands.
   • Potential impacts include delays, valuation adjustments, and new transaction structures.
   • Attorneys must stay ahead of regulatory shifts to guide buyers and sellers effectively.

The Opportunity

For companies that embrace these changes, the mandate offers a chance to differentiate themselves as trusted, compliant players in the life sciences arena.

If you're preparing for the challenges and opportunities of this regulatory shift, The Kulkarni Law Firm is here to help navigate these hurdles. Let's talk about how to adapt and thrive under the new gold standard.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Florida medical clinic owner and staff were charged with falsifying clinical trial data. According to the indictment, from September 2015 to March 2018, the defendants at AMB Research Center in Miami fabricated clinical trial data for profit. They knowingly enrolled subjects who did not meet eligibility criteria, falsified lab data and medical records, and falsely represented that subjects were taking the studied drug when they were not.

Co-owners Montalvo and Garmendia, were charged, along with Portela, a pharmacy technician at the research center. This case serves as a reminder that the FDA and DOJ do not overlook past misconduct, emphasizing that even those who are not principal investigators can face legal repercussions. The focus on clinical trial fraud remains a significant concern, with the DOJ highlighting it as one of their key enforcement pillars. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this reaction video, Darshan responds to claims about the effectiveness of prescribed medications. While patients often expect their drugs to work, a statement suggesting that only 20% of people benefit from these medications is misleading. Darshan emphasizes that the FDA focuses on ensuring drugs are not harmful and assesses efficacy based on their effectiveness for a sufficient number of individuals, rather than a simplistic percentage. He discusses the growing field of personalized medicine, which aims to tailor treatments to individual genetic makeups, but notes that predicting a drug's effectiveness for a specific person remains complex. Concepts like digital clones and genetic design offer hope for the future, but he advises viewers to approach these ideas with caution. Ultimately, Darshan encourages understanding the intricacies of drug efficacy while maintaining realistic expectations.

Support the show

www.kulkarnilawfirm.com